Back to top
more

Roche Holding (RHHBY)

(Delayed Data from OTC)

$41.71 USD

41.71
3,332,742

+0.28 (0.68%)

Updated Aug 23, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (90 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

4 Large-Cap Pharma Stocks That Outperformed the S&P This Year

by Zacks Equity Research

We take a look at a few Large Cap stocks, which have surpassed the S&P 500 index in 2017 due to upsides on both regulatory and pipeline fronts.

    ImmunoGen (IMGN) Soars Above 200% This Year: Here's Why

    by Zacks Equity Research

    ImmunoGen's (IMGN) shares shoot up in the year on rapid pipeline progress, positive study data and strategic collaborations.

      Arpita Dutt headshot

      Pharma Stock Roundup: Roche, MNK Announce Acquisition Agreements, Regulatory Updates from Novartis

      by Arpita Dutt

      Although it's been a relatively slow week, two acquisition deals were announced with Roche (RHHBY) saying it will acquire Ignyta while Mallinckrodt will buy Sucampo.

        Celgene (CELG) in Troubled Waters in '17: What Does 2018 Hold?

        by Zacks Equity Research

        Celgene's (CELG) stock has been under pressure due to pipeline setbacks. We expect an acquisition in the offing to bolster its portfolio.

          Will Exelixis (EXEL) be Able to Carry '17 Momentum in 2018?

          by Zacks Equity Research

          Exelixis (EXEL) had a phenomenal run in 2017 driven by sales of Cabometyx and we expect the momentum to continue in 2018 on the back of the label expansion of the drug.

            Roche (RHHBY) Clinches $1.7-Billion Deal to Acquire Ignyta

            by Zacks Equity Research

            Roche (RHHBY) is set to acquire Ignyta for $27 per share or a total value of $1.7 billion to strengthen its oncology pipeline further.

              Celgene (CELG) Down on Discouraging Data on Revlimid

              by Zacks Equity Research

              Celgene (CELG)'s stock declined as the phase III study, REVELANCE, for the label expansion of key drug Revlimid for untreated follicular lymphoma patients failed.

                Cancer Space Update: FDA Approves Label Expansion of 4 Drugs

                by Zacks Equity Research

                The FDA has approved label expansion of four different drugs from Roche, Exelixis, Pfizer and Bristol-Myers. However, Celgene faced a setback as Revlimid failed in a phase III study.

                  Roche's Perjeta Gets FDA Nod for Post Surgery Breast Cancer

                  by Zacks Equity Research

                  Roche's (RHHBY) Perjeta in combination with Herceptin and chemotherapy (the Perjeta-based regimen), gets FDA nod for adjuvant (after surgery) treatment of HER2-positive early breast cancer at high risk of recurrence

                    What's Happening in Advanced Renal Cell Carcinoma Space?

                    by Zacks Equity Research

                    The advanced renal cell carcinoma space is back in focus as the FDA approved Cabometyx for treatment-naive patients. Investors will keep an eye on other combination therapies being evaluated for the treatment of advanced RCC,

                      Exelixis' Cabometyx Gets FDA Nod for First-Line Kidney Cancer

                      by Zacks Equity Research

                      Exelixis (EXEL) received a significant boost with the approval of label expansion of lead drug Cabometyx for first-line kidney cancer.

                        AstraZeneca's Tagrisso Label Expansion Filing Accepted by FDA

                        by Zacks Equity Research

                        AstraZeneca's (AZN) regulatory application for label expansion of Tagrisso to include treatment of NSCLC with EGFR mutation in first-line setting has been accepted by the FDA.

                          Mylan Announces IPR Proceedings for Sanofi's Lantus Patents

                          by Zacks Equity Research

                          Mylan (MYL) announced that interpartes review (IPR) proceedings has been initiated by PTAB regarding two Orange Book-listed patents, U.S. Patent Nos. 7,476,652 and 7,713,930 owned by Sanofi.

                            Cancer Space Update: Roche, Pfizer & Regeneron Make Data Presentations

                            by Zacks Equity Research

                            Several presentations at the annual meeting of the American Society of Hematology grab headlines in the cancer space.

                              Arpita Dutt headshot

                              Pharma Stock Roundup: Teva Announces Major Job Cuts, Lilly Provides 2018 Outlook

                              by Arpita Dutt

                              This week's pharma sector highlights include ASH data, Teva's restructuring announcement and Lilly's (LLY) 2018 outlook.

                                Pfizer's Second Biosimilar of Remicade Receives FDA Approval

                                by Zacks Equity Research

                                The FDA approves Ixifi, Pfizer's (PFE) second biosimilar version of Johnson & Johnson's rheumatoid arthritis drug, Remicade. Ixifi receives the nod for all approved indications of Remicade.

                                  Roche/AbbVie Report Positive Phase III Results on Venclexta

                                  by Zacks Equity Research

                                  Roche (RHHBY) announced positive results from a pivotal phase III study, MURANO, evaluating Venclexta plus Rituxan compared to bendamustine plus Rituxan (BR) for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL).

                                    Novartis Announces Positive Data on Sickle Cell Disease Drug

                                    by Zacks Equity Research

                                    Novartis (NVS) announced positive data from a phase II study, SUSTAIN, on pipeline candidate crizanlizumab which deferred the time to first sickle cell pain crisis (SCPC) in patients compared to placebo in key subgroups of adult patients with sickle cell.

                                      Roche Reports Positive Data from Tecentriq Combination Study

                                      by Zacks Equity Research

                                      Roche reported positive data from a combination study of Tecentriq and Avastin in metastatic renal cell carcinoma patients.

                                        Swarup Gupta headshot

                                        Foreign Stock Roundup: Bank of Montreal Q4 Earnings Decline, Rio Tinto Lowers '17 Capital Spending Target

                                        by Swarup Gupta

                                        Investors in Europe remained focused on Brexit negotiations and the Senate's decision to approve a new tax Bill last week.

                                          Puma (PBYI) Stock Up More than 200% This Year: Here's Why

                                          by Zacks Equity Research

                                          Puma's (PBYI) shares skyrocket in the year so far on the approval of its cancer drug Nerlynx in the United States coupled with strategic collaborations.

                                            Arpita Dutt headshot

                                            Pharma Stock Roundup: FDA Nod for NVO's Ozempic, Second Indication for Lilly's Taltz

                                            by Arpita Dutt

                                            FDA approval for Novo Nordisk's (NVO) type II diabetes drug, a second indication for Lilly's Taltz, and the approval of the first Herceptin biosimilar were the key highlights this week.

                                              Roche Reports Tecentriq/Avastin Lung Cancer Study Data

                                              by Zacks Equity Research

                                              Roche (RHHBY) announced interim results from the phase III IMpower150 study of Tecentriq and Avastin plus chemotherapy in people with advanced form of lung cancer.

                                                Clovis' sNDA for Rubraca Gets Priority Review in the U.S.

                                                by Zacks Equity Research

                                                The FDA grants priority review to Clovis' (CLVS) supplemental new drug application for its marketed drug, Rubraca's label expansion as a maintenance treatment for ovarian cancer.

                                                  Roche's Avastin Gets Full FDA Approval for Brain Cancer

                                                  by Zacks Equity Research

                                                  Roche (RHHBY) announced that the FDA converted accelerated approval for Avastin to full approval for the patients previously treated for aggressive form of brain cancer.